# EDGAR Filing Document

**Accession Number:** 0000012239
**File Stem:** 0001213900-23-001419
**Filing Date:** 2023-1
**Character Count:** 5065
**Document Hash:** 323424d87f09746fad36f133337c2efd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-001419.hdr.sgml**: 20230106

**ACCESSION NUMBER**: 0001213900-23-001419

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230101

**FILED AS OF DATE**: 20230106

**DATE AS OF CHANGE**: 20230106

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Devall Christopher Franklin
- **CENTRAL INDEX KEY:** 0001961226

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-05576
- **FILM NUMBER:** 23515578

**MAIL ADDRESS:**
- **STREET 1:** DOMINARI HOLDINGS INC.
- **STREET 2:** ONE ROCKEFELLER PLAZA, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10020
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dominari Holdings Inc.
- **CENTRAL INDEX KEY:** 0000012239
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 520849320
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** ONE ROCKEFELLER PLAZA, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10020
- **BUSINESS PHONE:** 347-321-7646

**MAIL ADDRESS:**
- **STREET 1:** ONE ROCKEFELLER PLAZA, 11TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10020

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AIkido Pharma Inc.
- **DATE OF NAME CHANGE:** 20210111

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aikido Pharma Inc.
- **DATE OF NAME CHANGE:** 20200317

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SPHERIX INC
- **DATE OF NAME CHANGE:** 20010815

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Devall Christopher Franklin<br><sub>(Last) (First) (Middle)</sub><br>ONE ROCKEFELLER PLAZA,<br>11TH FLOOR<br><sub>(Street)</sub><br>NEW YORK, NY 10020<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Dominari Holdings Inc. [ DOMH ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Operating Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 13835<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

### Footnotes:

(1) On December 16, 2022, the reporting person purchased 3,000 shares of common stock in the public market at an average price of $3.71 per share. On December 19, 2022, the reporting person purchased 1,389 shares of common stock in the public market at $3.599 per share. On December 21, 2022, the reporting person purchased 1,378 shares of common stock in the public market at $3.6599 per share. On July 1, 2022, the reporting person was granted 8,068 shares of restricted stock pursuant to the Company's 2014 Equity Incentive Plan which fully vested on January 1, 2023.

**Signature:** /s/ Christopher Devall  
**Date:** 2023-01-06

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**